Annette Jackson

Annette Jackson serves as a key procurement professional within the Defense Health Agency, supporting the agency’s mission to deliver secure, high-quality healthcare services to uniformed service members, retirees, and their families. She manages acquisitions centered on in-vitro diagnostic substances and related laboratory technologies, ensuring the availability of critical testing infrastructure for clinical readiness and force health protection. Her work directly enables the DHA’s strategic priorities in modernizing diagnostic capabilities and strengthening pharmaceutical and medical supply chains across global military medical facilities. She handles competitive solicitations under FAR and DFARS guidelines, focusing on complex, high-stakes procurements requiring strict regulatory compliance and technical validation. Jackson maintains consistent partnerships with specialized vendors including Dependable On-Site Scan & Shred, Inc., Hanith Bioscience, LLC, Livion Technology, LLC, I-2-I Solutions, Inc., and Draeger Inc., all of which provide niche diagnostic reagents, laboratory automation systems, and point-of-care testing technologies. Her contracting patterns reflect a preference for established, technically proficient suppliers with proven capabilities in FDA-regulated medical manufacturing and sterile product distribution. These relationships are characterized by long-term performance, technical alignment with DHA clinical standards, and adherence to stringent quality control protocols. Jackson’s procurement portfolio exhibits no set-aside preferences, with 100% of awards issued under full and open competition. This reflects a strategic emphasis on technical excellence and supply chain reliability over socioeconomic classifications, prioritizing mission-critical performance over socioeconomic targeting. While small business participation is not formally incentivized in her portfolio, vendors of all sizes must meet rigorous performance and compliance benchmarks. Her primary NAICS focus is 325413—In-Vitro Diagnostic Substance Manufacturing—indicating deep expertise in procuring reagents, assay kits, and diagnostic platforms used in military medical laboratories. She specializes in acquiring products that support infectious disease surveillance, biodefense readiness, and rapid clinical diagnostics, requiring deep understanding of CLIA, ISO 13485, and FDA 21 CFR Part 820 regulatory frameworks.